BenevolentAI
drug development is failing patients expensive high risk long cycles poor high societal cost spent per year on drug in average and to market cost per drug overall failure rate in drug development years to market diseases with no effective treatment leading drugs effective on of patients approved cancer drugs have poor response rates with only showing an advantage the human body is an incredibly complex information system made up of over trillion cells the underlying mechanisms of complex multifactorial diseases are often misunderstood scientists can possibly keep up with exponential growth of research and data of data generated last year alone gaining a clear understanding of the underlying molecular mechanisms based on the totality of available data is a vital step in the development of successful and treatments | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
8 of 42
Related slides by other companies
DoubleVerify
Results
November 2023
leading the market in privacy data security us us | DoubleVerify
Absci
Investor Conference
January 2023
is solving the problem of scalable biological data enabling true generative for drug discovery | Absci
Alkermes
Investor Conference
January 2024
proven drug development capabilities | Alkermes
Marpai
Investor Conference
January 2024
growing market | Marpai
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io